These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20048440)

  • 1. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers].
    Kimura G
    Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive agents and renal protection: calcium channel blockers.
    Saruta T; Kanno Y; Hayashi K; Konishi K
    Kidney Int Suppl; 1996 Jun; 55():S52-6. PubMed ID: 8743511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal protective action of T-, L-, and N-type Ca channel blockers].
    Hayashi K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():654-61. PubMed ID: 15171451
    [No Abstract]   [Full Text] [Related]  

  • 5. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of anti-hypertensive drugs on glomerular hemodynamics.
    Ito S; Abe K
    Nihon Jinzo Gakkai Shi; 1996 Mar; 38(3):115-8. PubMed ID: 8721331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular effects of calcium channel antagonists: new evidence.
    Richard S
    Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can calcium channel blockers preserve renal function better than diuretics during antihypertensive treatment?
    Fukuda M; Kimura G
    Arch Intern Med; 2005 Jun; 165(11):1312; author reply 1312-3. PubMed ID: 15956015
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and JSH2009].
    Ebina T; Kimura K; Umemura S
    Clin Calcium; 2010 Jan; 20(1):16-22. PubMed ID: 20048429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension.
    Hayashi K; Ozawa Y; Fujiwara K; Wakino S; Kumagai H; Saruta T
    Am J Nephrol; 2003; 23(4):229-44. PubMed ID: 12840599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcium antagonists: current and future applications based on new evidence. Combination antihypertensive therapy with calcium channel blockers].
    Ishimitsu T
    Clin Calcium; 2010 Jan; 20(1):52-60. PubMed ID: 20048434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].
    Takahara A
    Clin Calcium; 2010 Jan; 20(1):24-30. PubMed ID: 20048430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?
    Segura J; García-Donaire JA; Ruilope LM
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):422-6. PubMed ID: 17693756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal vascular effects of calcium channel blockers in hypertension.
    Benstein JA; Dworkin LD
    Am J Hypertens; 1990 Dec; 3(12 Pt 2):305S-312S. PubMed ID: 2078317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers and nephroprotection.
    Ungar A; Di Serio C; Lambertucci L; Monami M; Masotti G
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):31-9. PubMed ID: 16640171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.